Publications by authors named "Lowell Hart"

Claim this Profile
R
Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2- early breast cancer.
Joyce O'Shaughnessy, Sara M Tolaney, Denise A Yardley, Lowell Hart, Pedram Razavi

Breast· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase 2 trial of pembrolizumab alone or in combination with low dose chemotherapy for patients with non-small cell lung cancer and poor performance status.
Safoa Addo, Thomas Lycan, David R Soto-Pantoja, Yu-Ting Tsai, Ericson Stoen, Lowell Hart

Lung Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlation analysis of invasive disease-free survival and overall survival in a real-world population of patients with HR+/HER2- early breast cancer.
Stephanie L Graff, Sara M Tolaney, Lowell L Hart, Pedram Razavi, Wolfgang Janni

Cancer· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2- advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trials.
Lowell L Hart, Seock-Ah Im, Sara M Tolaney, Mario Campone, Timothy Pluard

Eur J Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT.
Paolo Tarantino, Nabihah Tayob, Guillermo Villacampa, Chau Dang, Denise A Yardley, Lowell Hart

J Clin Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Personalized Therapy Selection by Integration of Molecular Cancer Classification by the 92-Gene Assay and Tumor Profiling in Patients With Cancer of Unknown Primary.
Harry E Fuentes Bayne, Pashtoon M Kasi, Li Ma, Lowell L Hart, Jenna Wong

JCO Precis Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Outcomes of Trilaciclib Among Patients with Extensive-Stage Small Cell Lung Cancer Receiving Chemotherapy.
Jerome Goldschmidt, Lowell Hart, Jeffrey Scott, Kristen Boykin, Ray Bailey

Adv Ther· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors.
Todd M Bauer, Kathleen N Moore, Janet S Rader, Fiona Simpkins, Alain C Mita, Lowell Hart

Target Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
X
XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease.
Peter Schmid, Javier Cortes, Ana Joaquim, Noelia Martínez Jañez, Serafín Morales, Lowell Hart

Breast Cancer Res· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Burden of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer: A retrospective study from community oncology practices.
Lowell Hart, Augustina Ogbonnaya, Kristen Boykin, Kathryn Deyoung, Ray Bailey

Cancer Med· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.
Gabriel N Hortobagyi, Salomon M Stemmer, Howard A Burris, Yoon-Sim Yap, Gabe S Sonke, Lowell Hart

N Engl J Med· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial.
Romualdo Barroso-Sousa, Paolo Tarantino, Nabihah Tayob, Chau Dang, Denise A Yardley, Lowell Hart

NPJ Breast Cancer· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR/HER2 Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1).
Aditya Bardia, Sara A Hurvitz, Angela DeMichele, Amy S Clark, Amelia Zelnak, Lowell Hart

Clin Cancer Res· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial).
Kathryn J Ruddy, Yue Zheng, Nabihah Tayob, Jiani Hu, Chau T Dang, Lowell L Hart

Breast Cancer Res Treat· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer.
Howard A Burris, Arlene Chan, Aditya Bardia, J Thaddeus Beck, Joohyuk Sohn, Lowell Hart

Br J Cancer· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial.
Sara M Tolaney, Nabihah Tayob, Chau Dang, Denise A Yardley, Steven J Isakoff, Lowell Hart

J Clin Oncol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients.
Costanza Paoletti, Meredith M Regan, Samuel M Niman, Emily M Dolce, Elizabeth P Darga, Lowell L Hart

NPJ Breast Cancer· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: A multicentre, randomised, double-blind, placebo-controlled Phase II trial.
Davey Daniel, Vladimer Kuchava, Igor Bondarenko, Oleksandr Ivashchuk, Sreekanth Reddy, Lowell Hart

Int J Cancer· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer.
Andrew Wardley, Javier Cortes, Louise Provencher, Kathy Miller, A Jo Chien, Lowell Hart

Breast Cancer Res Treat· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer.
Chao Li, Lowell Hart, Taofeek K Owonikoko, Raid Aljumaily, Caio Max Rocha Lima

Cancer Chemother Pharmacol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose-expansion cohort.
Jesus G Berdeja, Tara K Gregory, Edward A Faber, Lowell L Hart, Joseph R Mace

Am J Hematol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study.
Lowell L Hart, Renata Ferrarotto, Zoran G Andric, J Thaddeus Beck, Janakiraman Subramanian

Adv Ther· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer.
Ian Krop, Vandana Abramson, Marco Colleoni, Tiffany Traina, Frankie Holmes, Lowell Hart

Clin Cancer Res· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours.
Devalingam Mahalingam, Manish R Patel, Jasgit C Sachdev, Lowell L Hart, Niels Halama

Br J Clin Pharmacol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advanced Squamous Cell Carcinoma of the Lung: Current Treatment Approaches and the Role of Afatinib.
Edgardo S Santos, Lowell Hart

Onco Targets Ther· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis